Browsing by Author "Zirn, Birgit"
Now showing 1 - 18 of 18
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settingsA 16q12 Microdeletion in a Boy With Severe Psychomotor Delay, Craniofacial Dysmorphism, Brain and Limb Malformations, and a Heart Defect(Wiley-blackwell, 2012)
;Shoukier, Moneef ;Wickert, Julia ;Schroeder, Julia ;Bartels, Iris ;Auber, Bernd; ; ;Weise, Dagmar; ;Zirn, BirgitInterstitial deletions of the proximal chromosome 16q are rare. To date, only six cases with molecularly well-characterized microdeletions within this chromosomal region have been described. We report on a patient with severe psychomotor delay, dysmorphic features, microcephaly and hypoplasia of the corpus callosum, epilepsy, a heart defect, and pronounced muscular hypotonia. Array comparative genomic hybridization (aCGH) revealed that the patient's features were likely caused by a 4.7 Mb de novo deletion on chromosome 16q12.1q12.2, which was confirmed by quantitative real-time PCR (qPCR). The psychomotor delay and craniofacial dysmorphism are more severe in our patient than previously reported patients. Unmasked recessive mutations in the ZNF423 and FTO genes on the remaining allele were excluded as the putative cause for this severe phenotype. In conclusion, the phenotypic spectrum of microdeletions in 16q12 is broad and comprises variable degrees of psychomotor delay and intellectual disability, craniofacial anomalies, and additional features, including heart defects, brain malformations, and limb anomalies. (C) 2011 Wiley Periodicals, Inc. - Some of the metrics are blocked by yourconsent settingsArray CGH in patients with developmental delay or intellectual disability: are there phenotypic clues to pathogenic copy number variants?(2013)
;Shoukier, M.; ;Auber, B. ;Wickert, J. ;Schroeder, J.; ; ;Bartels, I. ;Alsat, E. A.; ;Grzmil, P. ;Schulze, S.; ;Weise, Dagmar ;Borchers, M. ;Hobbiebrunken, E. ;Roebl, M.; ; Zirn, BirgitArray comparative genomic hybridization (array CGH) is now widely adopted as a first-tier clinical diagnostic test in individuals with unexplained developmental delay/intellectual disability (DD/ID) and congenital anomalies. Our study aimed at enlarging the phenotypic spectrum associated with clinically relevant copy number variants (CNVs) as well as delineating clinical criteria, which may help separating patients with pathogenic CNVs from those without pathogenic CNVs. We performed a retrospective review of clinical and array CGH data of 342 children with unexplained DD/ID. The phenotypic features of patients with clinically significant CNV were compared with those without pathogenic CNVs. Array CGH detected pathogenic CNVs in 13.2% of the patients. Congenital anomalies, especially heart defects, as well as primary microcephaly, short stature and failure to thrive were clearly more frequent in children with pathogenic CNVs compared with children with normal array CGH results. Thus, we assume that in patients with unexplained DD/ID, array CGH will more probably detect a significant CNV if any of these features is part of the patient's phenotype. - Some of the metrics are blocked by yourconsent settingsChondrodysplasia and growth failure in children after early hematopoietic stem cell transplantation for non‐oncologic disorders(2021)
;Botto, Lorenzo D. ;Meeths, Marie ;Campos‐Xavier, Belinda ;Bergamaschi, Rosalba ;Mazzanti, Laura ;Scarano, Emanuela ;Finocchi, Andrea ;Cancrini, Caterina ;Zirn, Birgit; ; ;Alanay, Yasemin ;Jones, Wendy D. ;Irving, Melita ;Sabir, Ataf ;Henter, Jan‐Inge ;Borgström, Birgit ;Nordgren, Ann ;Hammarsjö, Anna ;Putti, Caterina ;Mozzato, Chiara ;Zuccarello, Daniela ;Nishimura, Gen ;Bonafè, Luisa ;Grigelioniene, Giedre ;Unger, SheilaSuperti‐Furga, Andrea - Some of the metrics are blocked by yourconsent settingsConcurrence of Dystonia 1 and Charcot-Marie-Tooth Neuropathy, Type 1 A, in a Large Family(Wiley-blackwell, 2011)
;Zirn, Birgit ;Korenke, Christoph ;Wagner, Michael ;Rudnik-Schoeneborn, SabineMueller, Ulrich - Some of the metrics are blocked by yourconsent settingsContinuing role for classical cytogenetics: Case report of a boy with ring syndrome caused by complete ring chromosome 4 and review of literature(2017-03)
;Burgemeister, Anna Lena ;Daumiller, Eva ;Dietze-Armana, Ilona ;Klett, Christine; ; ; ;Centonze, Izabela ;Rettenberger, Günther ;Mehnert, KarlZirn, BirgitConstitutional ring chromosomes can be found for all human chromosomes and are very rare chromosomal abnormalities. A complete ring chromosome without loss of genetic material results from fusion of subtelomeric regions or telomere-telomere fusion. In cases of complete ring chromosome, an increased incidence of severe growth failure with no or only minor anomalies has been observed and attributed to ring syndrome. Ring syndrome is thought to be caused by "dynamic mosaicism" due to ring instability. We report a 6-year-old boy with de novo ring chromosome 4 and typical characteristics of the ring syndrome, namely, proportionate severe growth failure, microcephaly, and minor anomalies. Cytogenetic studies showed complete ring chromosome 4 with mitotic instability. Microarray gave normal results, thus excluding the loss of detectable genetic material. The literature of complete ring chromosome 4 is reviewed. Our case report supports the theory of ring syndrome. No studies about the effects and possible side effects of growth hormone therapy on patients with ring chromosomes have yet been published. We suggest that cytogenetic monitoring of the rate of secondary aberrations in patients with ring chromosome undergoing growth hormone therapy might be feasible. Since the diagnosis would have been missed by molecular karyotyping, our case report underlines the continuing role of classical cytogenetics for the evaluation of structural chromosomal abnormalities in patients with mental and/or physical anomalies. Standard karyotyping is still indispensable and should have an ongoing role as first-tier analysis together with molecular karyotyping. © 2017 Wiley Periodicals, Inc. - Some of the metrics are blocked by yourconsent settingsDe novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes(Nature Publishing Group, 2012)
;Riviere, Jean-Baptiste ;Mirzaa, Ghayda M. ;O’Roak, Brian J. ;Beddaoui, Margaret ;Alcantara, Diana ;Conway, Robert L. ;St-Onge, Judith ;Schwartzentruber, Jeremy A. ;Gripp, Karen W. ;Nikkel, Sarah M. ;Worthylake, Thea ;Sullivan, Christopher T. ;Ward, Thomas R. ;Butler, Hailly E. ;Kramer, Nancy A. ;Albrecht, Beate ;Armour, Christine M. ;Armstrong, Linlea ;Caluseriu, Oana ;Cytrynbaum, Cheryl ;Drolet, Beth A. ;Innes, A. Micheil ;Lauzon, Julie L. ;Lin, Angela E. ;Mancini, Grazia M. S. ;Meschino, Wendy S. ;Reggin, James D. ;Saggar, Anand K. ;Lerman-Sagie, Tally ;Uyanik, Goekhan ;Weksberg, Rosanna ;Zirn, Birgit ;Beaulieu, Chandree L. ;Majewski, Jacek ;Bulman, Dennis E. ;O’Driscoll, Mark ;Shendure, Jay ;Graham, John M., Jr. ;Boycott, Kym M.Dobyns, William B.Megalencephaly-capillary malformation (MCAP) and megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndromes are sporadic overgrowth disorders associated with markedly enlarged brain size and other recognizable features(1-5). We performed exome sequencing in 3 families with MCAP or MPPH, and our initial observations were confirmed in exomes from 7 individuals with MCAP and 174 control individuals, as well as in 40 additional subjects with megalencephaly, using a combination of Sanger sequencing, restriction enzyme assays and targeted deep sequencing. We identified de novo germline or postzygotic mutations in three core components of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. These include 2 mutations in AKT3, 1 recurrent mutation in PIK3R2 in 11 unrelated families with MPPH and 15 mostly postzygotic mutations in PIK3CA in 23 individuals with MCAP and 1 with MPPH. Our data highlight the central role of PI3K-AKT signaling in vascular, limb and brain development and emphasize the power of massively parallel sequencing in a challenging context of phenotypic and genetic heterogeneity combined with postzygotic mosaicism. - Some of the metrics are blocked by yourconsent settingsFOXG1 syndrome: genotype–phenotype association in 83 patients with FOXG1 variants(2017)
;Mitter, Diana ;Pringsheim, Milka ;Kaulisch, Marc ;Plümacher, Kim Sarah ;Schröder, Simone ;Warthemann, Rita ;Abou Jamra, Rami ;Baethmann, Martina ;Bast, Thomas ;Büttel, Hans-Martin ;Cohen, Julie S ;Conover, Elizabeth ;Courage, Carolina ;Eger, Angelika ;Fatemi, Ali ;Grebe, Theresa A ;Hauser, Natalie S ;Heinritz, Wolfram ;Helbig, Katherine L ;Heruth, Marion ;Huhle, Dagmar ;Höft, Karen ;Karch, Stephanie ;Kluger, Gerhard ;Korenke, G Christoph ;Lemke, Johannes R ;Lutz, Richard E ;Patzer, Steffi ;Prehl, Isabelle ;Hoertnagel, Konstanze ;Ramsey, Keri ;Rating, Tina ;Rieß, Angelika ;Rohena, Luis ;Schimmel, Mareike ;Westman, Rachel ;Zech, Frank-Martin; ; ;Zirn, Birgit - Some of the metrics are blocked by yourconsent settingsFrequency of GCH1 deletions in dopa-responsive dystonia(B M J Publishing Group, 2008)
;Zirn, Birgit ;Steinberger, D. ;Troidl, C.; ;von der Hagen, Maja ;Feiner, C. ;Henkel, AndreasMueller, U.We performed a systematic study on the frequency of point mutations and deletions of the gene GCH1 in dopa-responsive dystonia (DRD). A total of 136 dystonia patients were studied. Fifty of these had a sustained response to oral L-Dopa therapy (group 1: definite diagnosis of DRD), whereas the response to L-Dopa was incomplete or not tested in 86 patients (group 2: possible diagnosis of DRD). We found a GCH1 point mutation in 27 patients of group 1 (54%) and in four patients of group 2 (5%). Of these, nine single and one double mutation have not been described before. GCH1 deletions were detected in four patients of group 1 (8%) and in one patient of group 2 (1%). Among GCH1 point-mutation-negative patients with a definite diagnosis of DRD (group 1), the frequency of GCH1 deletions was 17% (4/23). We conclude that GCH1 deletion analysis should be incorporated into the routine molecular diagnosis of all patients with DRD with a sustained response to L-Dopa. - Some of the metrics are blocked by yourconsent settingsGenetics of intellectual disability in consanguineous families(2018)
;Hu, Hao ;Kahrizi, Kimia ;Musante, Luciana ;Fattahi, Zohreh ;Herwig, Ralf ;Hosseini, Masoumeh ;Oppitz, Cornelia ;Abedini, Seyedeh Sedigheh ;Suckow, Vanessa ;Larti, Farzaneh ;Beheshtian, Maryam ;Lipkowitz, Bettina ;Akhtarkhavari, Tara ;Mehvari, Sepideh ;Otto, Sabine ;Mohseni, Marzieh ;Arzhangi, Sanaz ;Jamali, Payman ;Mojahedi, Faezeh ;Taghdiri, Maryam ;Papari, Elaheh ;Soltani Banavandi, Mohammad Javad ;Akbari, Saeide ;Tonekaboni, Seyed Hassan ;Dehghani, Hossein ;Ebrahimpour, Mohammad Reza ;Bader, Ingrid ;Davarnia, Behzad ;Cohen, Monika ;Khodaei, Hossein ;Albrecht, Beate ;Azimi, Sarah ;Zirn, Birgit ;Bastami, Milad ;Wieczorek, Dagmar ;Bahrami, Gholamreza ;Keleman, Krystyna ;Vahid, Leila Nouri ;Tzschach, Andreas; ;Gillessen-Kaesbach, Gabriele ;Varaghchi, Jamileh Rezazadeh ;Timmermann, Bernd ;Pourfatemi, Fatemeh ;Jankhah, Aria ;Chen, Wei ;Nikuei, Pooneh ;Kalscheuer, Vera M. ;Oladnabi, Morteza ;Wienker, Thomas F. ;Ropers, Hans-HilgerNajmabadi, HosseinAutosomal recessive (AR) gene defects are the leading genetic cause of intellectual disability (ID) in countries with frequent parental consanguinity, which account for about 1/7th of the world population. Yet, compared to autosomal dominant de novo mutations, which are the predominant cause of ID in Western countries, the identification of AR-ID genes has lagged behind. Here, we report on whole exome and whole genome sequencing in 404 consanguineous predominantly Iranian families with two or more affected offspring. In 219 of these, we found likely causative variants, involving 77 known and 77 novel AR-ID (candidate) genes, 21 X-linked genes, as well as 9 genes previously implicated in diseases other than ID. This study, the largest of its kind published to date, illustrates that high-throughput DNA sequencing in consanguineous families is a superior strategy for elucidating the thousands of hitherto unknown gene defects underlying AR-ID, and it sheds light on their prevalence. - Some of the metrics are blocked by yourconsent settingsIDENTIFICATION OF A NOVEL GERMLINE MECOM / EVI1 VARIANT THAT RUNS IN A PEDIGREE WITH RADIOULNAR SYNOSTOSIS AND AMEGAKARYOCYTIC THROMBOCYTOPENIA AND PREDISPOSES TO ADULT ONSET MYELOID MALIGNANCY(Ferrata Storti Foundation, 2017)
;Ripperger, Tim ;Hofmann, W.; ; ; ; ;Issing, P. R. ;Karnebogen, M. ;Schmidt, G. ;Auber, Bernd ;Schlegelberger, Brigitte ;Illig, Thomas ;Zirn, BirgitSteinemann, Doris - Some of the metrics are blocked by yourconsent settingsMDS1 and EVI1 complex locus (MECOM): a novel candidate gene for hereditary hematological malignancies(2018)
;Ripperger, Tim ;Hofmann, Winfried; ; ; ; ;Issing, Peter R. ;Karnebogen, Matthias ;Schmidt, Gunnar ;Auber, Bernd ;Schlegelberger, Brigitte ;Illig, Thomas ;Zirn, BirgitSteinemann, Doris - Some of the metrics are blocked by yourconsent settingsMicroduplication of 3p26.3 in Nonsyndromic Intellectual Disability Indicates an Important Role of CHL1 for Normal Cognitive Function(Georg Thieme Verlag Kg, 2013)
;Shoukier, Moneef ;Fuchs, Sigrid ;Schwaibold, Eva; ; ; Zirn, BirgitTerminal deletions of chromosome 3p26.3 confined to the CHL1 gene have previously been described in children with intellectual disability and epilepsy. Here, we report for the first time, a 3p26.3 duplication including only the CHL1 gene in an intellectually disabled girl with epilepsy. The penetrance of both deletions and duplications in 3p26.3 is reduced because all chromosomal imbalances were inherited from healthy parents. Further studies are needed to specify the pathogenic mechanism of 3p26.3 imbalances and to estimate recurrence risks in genetic counseling. However, the description of both deletions and duplications of chromosome 3p26.3 in nonsyndromic intellectual disability suggests that CHL1 is a dosage-sensitive gene with an important role for normal cognitive development. - Some of the metrics are blocked by yourconsent settingsMOLECULAR KARYOTYPING AS A NEW DIAGNOSTIC APPROACH TO SYNDROMES (WITH AND WITHOUT EPILEPSY)(Wiley-blackwell Publishing, Inc, 2009)Zirn, Birgit
- Some of the metrics are blocked by yourconsent settingsPaternally Inherited IGF2 Mutation and Growth Restriction.(2015-07-23)
;Begemann, Matthias ;Zirn, Birgit ;Santen, Gijs ;Wirthgen, Elisa ;Soellner, Lukas ;Büttel, Hans-Martin ;Schweizer, Roland ;van Workum, Wilbert ;Binder, GerhardEggermann, ThomasIn humans, mutations in IGF1 or IGF1R cause intrauterine and postnatal growth restriction; however, data on mutations in IGF2, encoding insulin-like growth factor (IGF) II, are lacking. We report an IGF2 variant (c.191C→A, p.Ser64Ter) with evidence of pathogenicity in a multigenerational family with four members who have growth restriction. The phenotype affects only family members who have inherited the variant through paternal transmission, a finding that is consistent with the maternal imprinting status of IGF2. The severe growth restriction in affected family members suggests that IGF-II affects postnatal growth in addition to prenatal growth. Furthermore, the dysmorphic features of affected family members are consistent with a role of deficient IGF-II levels in the cause of the Silver-Russell syndrome. (Funded by Bundesministerium für Bildung und Forschung and the European Union.). - Some of the metrics are blocked by yourconsent settingsPhenotypic spectrum associated with CASK loss-of-function mutations(B M J Publishing Group, 2011)
;Moog, Ute ;Kutsche, Kerstin ;Kortuem, Fanny ;Chilian, Bettina ;Bierhals, Tatjana ;Apeshiotis, Neophytos ;Balg, Stefanie ;Chassaing, Nicolas ;Coubes, Christine ;Das, Soma ;Engels, Hartmut ;van Esch, Hilde ;Grasshoff, Ute ;Heise, Marisol ;Isidor, Bertrand ;Jarvis, Joanna ;Koehler, Udo ;Martin, Thomas ;Oehl-Jaschkowitz, Barbara ;Ortibus, Els ;Pilz, Daniela T. ;Prabhakar, Prab ;Rappold, Gudrun ;Rau, Isabella ;Rettenberger, Guenther ;Schlueter, Gregor ;Scott, Richard H. ;Shoukier, Moonef ;Wohlleber, Eva ;Zirn, Birgit ;Dobyns, William B.Uyanik, GoekhanBackground Heterozygous mutations in the CASK gene in Xp11.4 have been shown to be associated with a distinct brain malformation phenotype in females, including disproportionate pontine and cerebellar hypoplasia. Methods The study characterised the CASK alteration in 20 new female patients by molecular karyotyping, fluorescence in situ hybridisation, sequencing, reverse transcriptase (RT) and/or quantitative real-time PCR. Clinical and brain imaging data of a total of 25 patients were reviewed. Results 11 submicroscopic copy number alterations, including nine deletions of similar to 11 kb to 4.5 Mb and two duplications, all covering (part of) CASK, four splice, four nonsense, and one 1 bp deletion are reported. These heterozygous CASK mutations most likely lead to a null allele. Brain imaging consistently showed diffuse brainstem and cerebellar hypoplasia with a dilated fourth ventricle, but of remarkably varying degrees. Analysis of 20 patients in this study, and five previously reported patients, revealed a core clinical phenotype comprising severe developmental delay/intellectual disability, severe postnatal microcephaly, often associated with growth retardation, (axial) hypotonia with or without hypertonia of extremities, optic nerve hypoplasia, and/or other eye abnormalities. A recognisable facial phenotype emerged, including prominent and broad nasal bridge and tip, small or short nose, long philtrum, small chin, and/or large ears. Conclusions These findings define the phenotypic spectrum associated with CASK loss-of-function mutations. The combination of developmental and brain imaging features together with mild facial dysmorphism is highly suggestive of this disorder and should prompt subsequent testing of the CASK gene. - Some of the metrics are blocked by yourconsent settingsRing chromosome 22 and neurofibromatosis type II: proof of two-hit model for the loss of the NF2 gene in the development of meningioma(Wiley-blackwell, 2012)
;Zirn, Birgit ;Arning, Larissa ;Bartels, I. ;Shoukier, Moneef ;Hoffjan, S. ;Neubauer, B.Hahn, A.Carriers of a ring chromosome 22 are mentally retarded and show variable facial dysmorphism. They may also present with features of neurofibromatosis type II (NF2) such as vestibular schwannomas and multiple meningiomas. In these cases, tumourigenesis has been suspected to be caused by the loss of both alleles of the NF2 gene, a tumour suppressor localized in 22q12.2. Here, we describe an 18-year-old patient with constitutional ring chromosome 22 and mental retardation who developed rapid-onset spastic paraparesis at the age of 15 years. The causative spinal meningioma at the level of T3, which compressed the spinal cord, was surgically removed, and the patient regained ambulation. Array comparative genomic hybridization (array CGH) and multiplex ligation-dependent probe amplification (MLPA) analyses in blood revealed a terminal deletion in 22q13.32, not comprising the NF2 gene. In tumour tissue, loss of the whole ring chromosome 22 including one NF2 gene due to mitotic instability constituted the likely first hit, while a point mutation in the other allele of the NF2 gene (c.784C>T, p.R262X) was shown as second hit. We review all cases from the literature and suggest clinical guidelines for surveillance of patients with ring chromosome 22. - Some of the metrics are blocked by yourconsent settingsStructural brain anomalies in patients with FOXG 1 syndrome and in Foxg1+/− mice(2019)
;Pringsheim, Milka ;Mitter, Diana ;Schröder, Simone ;Warthemann, Rita ;Plümacher, Kim ;Kluger, Gerhard ;Baethmann, Martina ;Bast, Thomas ;Braun, Sarah ;Büttel, Hans‐Martin ;Conover, Elizabeth ;Courage, Carolina ;Datta, Alexandre N. ;Eger, Angelika ;Grebe, Theresa A. ;Hasse‐Wittmer, Annette ;Heruth, Marion ;Höft, Karen ;Kaindl, Angela M. ;Karch, Stephanie ;Kautzky, Torsten ;Korenke, Georg C. ;Kruse, Bernd ;Lutz, Richard E. ;Omran, Heymut ;Patzer, Steffi ;Philippi, Heike ;Ramsey, Keri ;Rating, Tina ;Rieß, Angelika ;Schimmel, Mareike ;Westman, Rachel ;Zech, Frank‐Martin ;Zirn, Birgit ;Ulmke, Pauline A.; ; ; ;Staudt, MartinObjective: FOXG1 syndrome is a rare neurodevelopmental disorder associated with heterozygous FOXG1 variants or chromosomal microaberrations in 14q12. The study aimed at assessing the scope of structural cerebral anomalies revealed by neuroimaging to delineate the genotype and neuroimaging phenotype associations. Methods: We compiled 34 patients with a heterozygous (likely) pathogenic FOXG1 variant. Qualitative assessment of cerebral anomalies was performed by standardized re-analysis of all 34 MRI data sets. Statistical analysis of genetic, clinical and neuroimaging data were performed. We quantified clinical and neuroimaging phenotypes using severity scores. Telencephalic phenotypes of adult Foxg1+/- mice were examined using immunohistological stainings followed by quantitative evaluation of structural anomalies. Results: Characteristic neuroimaging features included corpus callosum anomalies (82%), thickening of the fornix (74%), simplified gyral pattern (56%), enlargement of inner CSF spaces (44%), hypoplasia of basal ganglia (38%), and hypoplasia of frontal lobes (29%). We observed a marked, filiform thinning of the rostrum as recurrent highly typical pattern of corpus callosum anomaly in combination with distinct thickening of the fornix as a characteristic feature. Thickening of the fornices was not reported previously in FOXG1 syndrome. Simplified gyral pattern occurred significantly more frequently in patients with early truncating variants. Higher clinical severity scores were significantly associated with higher neuroimaging severity scores. Modeling of Foxg1 heterozygosity in mouse brain recapitulated the associated abnormal cerebral morphology phenotypes, including the striking enlargement of the fornix. Interpretation: Combination of specific corpus callosum anomalies with simplified gyral pattern and hyperplasia of the fornices is highly characteristic for FOXG1 syndrome. - Some of the metrics are blocked by yourconsent settingsThe Phenotypic Spectrum of PRRT2-Associated Paroxysmal Neurologic Disorders in Childhood(MDPI, 2020)
;Döring, Jan Henje ;Saffari, Afshin ;Bast, Thomas; ;Ehrhardt, Laura ;Fazeli, Walid ;Janzarik, Wibke G. ;Kluger, Gerhard ;Muhle, Hiltrud ;Møller, Rikke S. ;Platzer, Konrad ;Santos, Joana Larupa ;Bache, Iben ;Bertsche, Astrid ;Bonfert, Michaela ;Borggräfe, Ingo ;Broser, Philip J. ;Datta, Alexandre N. ;Hammer, Trine Bjørg ;Hartmann, Hans ;Hasse-Wittmer, Anette ;Henneke, Marco ;Kühne, Hermann ;Lemke, Johannes R. ;Maier, Oliver ;Matzker, Eva ;Merkenschlager, Andreas ;Opp, Joachim ;Patzer, Steffi ;Rostasy, Kevin ;Stark, Birgit ;Strzelczyk, Adam ;von Stülpnagel, Celina ;Weber, Yvonne ;Wolff, Markus ;Zirn, Birgit ;Hoffmann, Georg Friedrich ;Kölker, Stefan ;Syrbe, Steffen ;Döring, Jan Henje; Division of Paediatric Epileptology, Centre for Paediatric and Adolescent Medicine, University Hospital Heidelberg, 69120 Heidelberg, Germany, jan.doering@med.uni-heidelberg.de ;Saffari, Afshin; Division of Paediatric Neurology and Metabolic Medicince, Centre for Paediatric and Adolescent Medicine, University Hospital, 69120 Heidelberg, Germany, Afshin.Saffari@med.uni-heidelberg.de ;Bast, Thomas; Epilepsy Center Kork, Medical Faculty of the University of Freiburg, 77694 Kehl, Germany, tbast@epilepsiezentrum.de Medical Faculty, University Hospital Freiburg, 79085 Freiburg, Germany, tbast@epilepsiezentrum.de ;Brockmann, Knut; Interdisciplinary Pediatric Center for Children with Developmental Disabilities and Severe Chronic Disorders, Children’s Hospital, University Medical Center, 37075 Göttingen, Germany, kbrock@med.uni-goettingen.de ;Ehrhardt, Laura; Department of Pediatrics, University Medicine Mainz, 55131 Mainz, Germany, Laura.Ehrhardt@unimedizin-mainz.de ;Fazeli, Walid; Pediatric Neurology, Department of Pediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany, walid.fazeli@uk-koeln.de Institute for Molecular and Behavioral Neuroscience, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany, walid.fazeli@uk-koeln.de ;Janzarik, Wibke G.; Department of Neuropediatrics and Muscle Disorders, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany, wibke.janzarik@uniklinik-freiburg.de ;Kluger, Gerhard; Clinic for Neuropediatrics and Neurorehabilitation, Epilepsy Center for Children and Adolescents, Schoen Clinic Vogtareuth, 83569 Vogtareuth, Germany, GKluger@schoen-klinik.de Research Institute for Rehabilitation, Transition and Palliation, PMU Salzburg, 5020 Salzburg, Austria, GKluger@schoen-klinik.de ;Muhle, Hiltrud; Department of Neuropediatrics, University Medical Center Schleswig-Holstein, Christian-Albrechts University, 24105 Kiel, Germany, Hiltrud.Muhle@uksh.de ;Møller, Rikke S.; Danish Epilepsy Centre, 4293 Dianalund, Denmark, rimo@filadelfia.dk Institute for Regional Health Research, University of Southern Denmark, 5230 Odense, Denmark, rimo@filadelfia.dk ;Platzer, Konrad; Institute of Human Genetics, University of Leipzig Medical Center, 04103 Leipzig, Germany, konrad.platzer@medizin.uni-leipzig.de ;Santos, Joana Larupa; Wilhelm Johannsen Centre for Functional Genome Research, Department of Cellular and Molecular Medicine, University of Copenhagen, 2200 Copenhagen, Denmark, joana.santos@sund.ku.dk Department of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark, joana.santos@sund.ku.dk ;Bache, Iben; Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet and Department of Cellular and Molecular Medicine, University of Copenhagen, 2100 Copenhagen, Denmark, iben.bache@regionh.dk ;Bertsche, Astrid; Centre for Paediatric Research, University Hospital for Children and Adolescents, 04103 Leipzig, Germany, Astrid.Bertsche@med.uni-rostock.de Neuropaediatrics, University Hospital for Children and Adolescents, 18057 Rostock, Germany, Astrid.Bertsche@med.uni-rostock.de ;Bonfert, Michaela; Department of Pediatric Neurology, Developmental Medicine and Social Pediatrics, University of Munich, 80337 Munich, Germany, Michaela.Bonfert@med.uni-muenchen.de ;Borggräfe, Ingo; Department of Pediatric Neurology, Developmental Medicine and Social Pediatrics, University of Munich, 80337 Munich, Germany, Ingo.Borggraefe@med.uni-muenchen.de Epilepsy Center, University of Munich, 80337 Munich, Germany, Ingo.Borggraefe@med.uni-muenchen.de ;Broser, Philip J.; Neuropädiatrie, Ostschweizer Kinderspital, 9006 St. Gallen, Switzerland, PhilipJulian.Broser@kispisg.ch ;Datta, Alexandre N.; University Children’s Hospital Basel, 4031 Basel, Switzerland, alexandre.datta@ukbb.ch ;Hammer, Trine Bjørg; Danish Epilepsy Centre, 4293 Dianalund, Denmark, thamm@filadelfia.dk ;Hartmann, Hans; Hannover Medical School, Clinic for Pediatric Kidney, Liver and Metabolic Diseases, 30625 Hannover, Germany, hartmann.hans@mh-hannover.de ;Hasse-Wittmer, Anette; Klinikum Traunstein, 83278 Traunstein, Germany, Anette.Hasse@kliniken-sob.de ;Henneke, Marco; Department of Pediatrics and Adolescent Medicine, University Medical Center, Georg August University, 37075 Göttingen, Germany, hennekem@med.uni-goettingen.de ;Kühne, Hermann; Children’s Hospital, 84503 Alt-Neuötting, Germany, h.kuehne@kinderzentrum.de ;Lemke, Johannes R.; Institute of Human Genetics, University of Leipzig Medical Center, 04103 Leipzig, Germany, Lemke@medizin.uni-leipzig.de ;Maier, Oliver; Department of Child Neurology, Children’s Hospital, 9006 St. Gallen, Switzerland, oliver.maier@kispisg.ch ;Matzker, Eva; Neuropädiatrie, Carl-Thiem-Klinikum Cottbus, 03048 Cottbus, Germany, E.Matzker@ctk.de ;Merkenschlager, Andreas; Department of Neuropediatrics, University Hospital of Children, 04103 Leipzig, Germany, Andreas.Merkenschlager@medizin.uni-leipzig.de ;Opp, Joachim; Children’s Hospital, 46047 Oberhausen, Germany, joachim_opp@eko.de ;Patzer, Steffi; Hospital St. Elizabeth and St. Barbara, 06110 Halle, Germany, s.patzer@krankenhaus-halle-saale.de ;Rostasy, Kevin; Department of Pediatric Neurology, Children’s Hospital Datteln, Witten/Herdecke University, 45711 Datteln, Germany, k.rostasy@kinderklinik-datteln.de ;Stark, Birgit; Kepler Universitätsklinikum, 4020 Linz, Austria, Birgit.Stark@kepleruniklinikum.at ;Strzelczyk, Adam; Department of Neurology and Epilepsy Center Frankfurt Rhine-Main, Goethe University Frankfurt, 60528 Frankfurt am Main, Germany, strzelczyk@med.uni-frankfurt.de ;von Stülpnagel, Celina; Department of Pediatric Neurology, Developmental Medicine and Social Pediatrics, University of Munich, 80337 Munich, Germany, cvstuelpnagel@steinbeis.co Epilepsy Center, University of Munich, Germany and Paracelsus Medical University Salzburg, 5020 Salzburg, Austria, cvstuelpnagel@steinbeis.co ;Weber, Yvonne; Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, 72076 Tübingen, Germany, yweber@ukaachen.de Department of Neurology and Epileptology, University of Aachen, 52074 Aachen, Germany, yweber@ukaachen.de ;Wolff, Markus; Department of Pediatric Neurology, Vivantes Hospital Neukölln, 12351 Berlin, Germany, Markus.Wolff@vivantes.de ;Zirn, Birgit; Genetic Counselling and Diagnostic, Genetikum Stuttgart, 70173 Stuttgart, Germany, zirn@genetikum.de ;Hoffmann, Georg Friedrich; Division of Paediatric Neurology and Metabolic Medicince, Centre for Paediatric and Adolescent Medicine, University Hospital, 69120 Heidelberg, Germany, georg.hoffmann@med.uni-heidelberg.de ;Kölker, Stefan; Division of Paediatric Neurology and Metabolic Medicince, Centre for Paediatric and Adolescent Medicine, University Hospital, 69120 Heidelberg, Germany, Stefan.Koelker@med.uni-heidelberg.deSyrbe, Steffen; Division of Paediatric Epileptology, Centre for Paediatric and Adolescent Medicine, University Hospital Heidelberg, 69120 Heidelberg, Germany, steffen.syrbe@med.uni-heidelberg.de